Results 1 to 10 of about 20,386 (204)

Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up? [PDF]

Western Journal of Emergency Medicine, 2020
Alteplase is the only Food and Drug Administration-approved intravenous (IV) thrombolytic medication for acute ischemic stroke. However, multiple recent studies comparing tenecteplase and alteplase suggest that tenecteplase is at least as efficacious as ...
Tony Zitek, Ramsey Ataya, Isabel Brea
doaj   +3 more sources

Effect of Alteplase Use on Outcomes in Patients With Atrial Fibrillation: Analysis of the Initiation of Anticoagulation After Cardioembolic Stroke Study

Journal of the American Heart Association, 2021
Background Intravenous alteplase improves outcome after acute ischemic stroke without a benefit in 90‐day mortality. There are limited data on whether alteplase is associated with reduced mortality in patients with atrial fibrillation (AF)‐related ...
shadi yaghi, Eva Mistry, Adam H De Havenon   +2 more
exaly   +3 more sources

Comparative effectiveness of Tenecteplase and Alteplase for ischemic stroke: real-world data from a stroke center [PDF]

BMC Neurology
Background Tenecteplase (TNK) and Alteplase (rt-PA) are intravenous thrombolytics used in acute ischemic stroke (AIS). While Alteplase has long been the standard of care, TNK is now also approved for AIS by both the EMA and FDA.
Toska Maxhuni, Francesca Culaj, Merve-Melis Sayar, Priyanka Böttger, Samra Hamzic, Stefan T. Gerner, Tobias Braun, Maxime Viard, Martin Juenemann, Heidrun H. Krämer, Omar AlHaj Omar   +10 more
doaj   +2 more sources

Comparative effectiveness and safety of tenecteplase versus alteplase for intravenous thrombolysis in acute ischemic stroke: a retrospective study [PDF]

Frontiers in Neurology
BackgroundTenecteplase has been proposed as a practical alternative to alteplase for intravenous thrombolysis in acute ischemic stroke. Although randomised trials have demonstrated noninferiority, data from real-world comparative cohorts remain limited ...
Weili Zhao, Xi Zhang, Yang Zhao, Ruijie Zhao, Yalin Liu   +4 more
doaj   +2 more sources

Low-dose vs. standard-dose alteplase for Chinese patients with acute ischemic stroke: A propensity score analysis

Frontiers in Neurology, 2023
Background and purposePrevious studies have stimulated debates on low-dose alteplase administration in acute ischemic stroke (AIS) among the Asian population.
Jiawen Xu, Xi Chen, Yanan Xie, Yi Wang, Shidong Chen, Qiang Dong, Yi Dong, Kun Fang   +7 more
doaj   +1 more source

Outcomes and Treatment Complications of Intravenous Urokinase Thrombolysis in Acute Ischemic Stroke in China

Frontiers in Neurology, 2021
Background: Intravenous thrombolysis with alteplase benefits eligible patients with acute ischemic stroke. However, in some countries such as China, alteplase may be too expensive for low-income patients, and also for regions with low economic ...
Rongrong Zhang, Hui Wei, Yu Ren, Yanping Wu, Yetao Luo, Lei Zhang, Yingchao Huo, Jinzhou Feng, Philippe P. Monnier, Philippe P. Monnier, Philippe P. Monnier, Xinyue Qin   +11 more
doaj   +1 more source

Tenecteplase Thrombolysis in Posterior Circulation Stroke

Frontiers in Neurology, 2021
One in five ischaemic strokes affects the posterior circulation. Basilar artery occlusion is a type of posterior circulation stroke associated with a high risk of disability and mortality.
Fana Alemseged, Bruce C. V. Campbell
doaj   +1 more source

A comparison of low- versus standard-dose bridging alteplase in acute ischemic stroke mechanical thrombectomy using indirect methods

Therapeutic Advances in Neurological Disorders, 2023
Background: Whether low-dose alteplase is similar to standard-dose bridging alteplase prior to endovascular mechanical thrombectomy in patients with acute ischemic stroke (AIS) remains uncertain.
Wei Zheng, Hanhan Lei, Gareth Ambler, David J. Werring, Huiying Lin, Xiaojuan Lin, Yi Tang, Jing Wu, Zhaomin Lin, Nan Liu, Houwei Du   +10 more
doaj   +1 more source

Different doses of tenecteplase vs. alteplase for acute ischemic stroke within 4.5 hours of symptom onset: a network meta-analysis of randomized controlled trials

Frontiers in Neurology, 2023
BackgroundThe optimal dose of tenecteplase vs. alteplase for acute ischemic stroke (AIS) has yet to be established. Therefore, we included the latest randomized controlled trials (RCT) to assess the efficacy and safety of different doses of tenecteplase ...
Huo Liang, Xue Wang, Xuemei Quan, Shijian Chen, Bin Qin, Shuolin Liang, Qiuhui Huang, Jian Zhang, Zhijian Liang   +8 more
doaj   +1 more source

Use of carefully titrated ultra‐low doses of alteplase in infected haemothorax caused by initial alteplase use to drain loculated malignant pleural effusion

Respirology Case Reports, 2023
Alteplase as a fibrinolytic can be used to break up fibrin to encourage clot breakdown for clinical use. In the pleural space, it is used for symptomatic loculated malignant pleural effusions and pleural infections and can potentially avoid the need for ...
Jeong Suk Oh, Chris Yoo, Donny Wong
doaj   +1 more source